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Aims Much controversy exists concerning the efﬁcacy of primary prophylactic implantable cardioverter-deﬁbrillators
(ICDs) in patients with low ejection fraction due to coronary artery disease (CAD) or dilated cardiomyopathy
(DCM). This is also related to the bias created by function improving interventions added to ICD therapy, e.g. resyn-
chronization therapy. The aim was to investigate the efﬁcacy of ICD-only therapy in primary prevention in patients
with CAD or DCM.
Methods
and results
Public domain databases, MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials, were searched
from 1980 to 2009 for randomized clinical trials of ICD vs. conventional therapy. Two investigators independently
abstracted the data. Pooled estimates were calculated using both ﬁxed-effects and random-effects models. Eight
trials were included in the ﬁnal analysis (5343 patients). Implantable cardioverter-deﬁbrillators signiﬁcantly
reduced the arrhythmic mortality [relative risk (RR): 0.40; 95% conﬁdence interval (CI): 0.27–0.67] and all-cause
mortality (RR: 0.73; 95% CI: 0.64–0.82). Regardless of aetiology of heart disease, ICD beneﬁt was similar for
CAD (RR: 0.67; 95% CI: 0.51–0.88) vs. DCM (RR: 0.74; 95% CI: 0.59–0.93).
Conclusions The results of this meta-analysis provide strong evidence for the beneﬁcial effect of ICD-only therapy on the survival
of patients with ischaemic or non-ischaemic heart disease, with a left ventricular ejection fraction ≤35%, if they are 40
days from myocardial infarction and ≥3 months from a coronary revascularization procedure.
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Introduction
Sudden cardiac and arrhythmic death (SCD) account for approxi-
mately 50% of the mortality in patients with left ventricular dys-
function.
1 Life-threatening ventricular arrhythmias are involved in
the majority of SCD occurrences.
2 Randomized clinical trials
have shown that the implantable cardioverter-deﬁbrillator (ICD)
is the most effective therapy currently available to prevent SCD
by terminating ventricular arrhythmias.
3–6 Therefore, the ICD
has become the standard therapy for primary and secondary pre-
vention of SCD in patients with left ventricular dysfunction.
7,8 The
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therapy created not only possibilities to improve cardiac function
in subgroups, but also inﬂuenced the outcome with respect to
morbidity and mortality.
9,10 In contrast, concerns were raised on
the magnitude of the effectiveness of ICD therapy certainly in
this era when the majority of infarction patients receive primary
coronary intervention in a reasonable time frame.
11 Some compli-
cations became more evident in the past few years, and
co-morbidity became considered as limitation as it is associated
with a less favourable outcome.
12,13 Given these recent concerns
about ICD therapy, we performed a systematic review and
meta-analysis of randomized trials of primary prevention of SCD
in patients with heart failure due to coronary artery disease
(CAD) or dilated cardiomyopathy (DCM), which constitute the
largest two subgroups of potential ICD recipients. We examined
the efﬁcacy of ICD-only therapy without CRT on rates of all-cause
mortality and arrhythmic mortality. In addition, we assessed the
rates of delivered ICD therapies.
Methods
Search strategy
A comprehensive search of public domain databases was performed to
identify randomized clinical trials comparing ICD therapy with conven-
tional medical therapy in patients with left ventricular dysfunction. The
public domain databases MEDLINE (January 1980 to January 2009),
EMBASE (1991 to the last quarter of 2008), and the Cochrane
Central Register of Controlled Trials (last quarter of 2008) were
searched using the terms implantable cardioverter-deﬁbrillator, implanta-
ble deﬁbrillator, randomized controlled trials, clinical trials, mortality,
sudden death, and prevention. The search was restricted to humans
and English language literature. In addition, we performed a manual
search of secondary sources including references of initially identiﬁed
articles and a search of reviews, editorials, commentaries, and pro-
ceedings from international cardiology meetings.
Eligibility and data abstraction
Studies considered for inclusion met the following criteria: the design
was a randomized controlled clinical trial; patients were randomly
assigned to ICD-only therapy excluding CRT vs. conventional
medical therapy; the study population consisted of patients with left
ventricular dysfunction deemed to be at high risk for sudden cardiac
death or developing ventricular arrhythmias; and the main endpoints
included all-cause mortality, cardiac mortality, or arrhythmic mortality.
Trials in patients who survived sudden cardiac death or unstable ven-
tricular arrhythmias (secondary prevention) were excluded. We also
excluded trials in patients with inherited arrhythmic disorders, trials
that did not report any of the main endpoints of interest, or trials
with crossover rates greater than 50% between study groups.
The selection of studies, quality assessment, and data abstraction
were performed independently by two investigators (D.A.M.J.T. and
L.J.). The criteria for quality assessment included study design aspects
as randomized clinical trial, description of crossover, withdrawals and
dropouts, completeness of follow-up, and objectivity of the outcome
assessment.
14 Data regarding detailed inclusion criteria as patient
characteristics [number, mean age, gender, left ventricular ejection
fraction (LVEF)], ICD device type, duration of follow-up, rates of cross-
over, all-cause mortality, cardiac mortality, and arrhythmic mortality
(as available) were abstracted from each study. Studies were
grouped according to the aetiology of cardiomyopathy.
Data analysis
A meta-analysis of summary statistics from the individual trials was per-
formed. For each study, data regarding all-cause mortality were used to
calculate the risk ratios (RRs) and 95% conﬁdence intervals (CIs). The
RRs from each included trial were pooled using both ﬁxed- and
random-effects models that used weighting based on the inverse of
the variance calculated according to DerSimonian and Laird.
15 Evi-
dence of statistical heterogeneity among the trial-speciﬁc RRs was
checked and quantiﬁed by the I
2 statistic, and a P-value ≤0.05 was con-
sidered statistically signiﬁcant. When no signiﬁcant statistical hetero-
geneity was identiﬁed, the ﬁxed effect was preferentially used as the
summary measure. In case of statistical heterogeneity, sensitivity analy-
sis was performed to assess the contribution of each study to the
pooled estimate by excluding individual studies one at a time and
the pooled estimate was recalculated for the remaining studies.
When pooled analysis still resulted in a signiﬁcant heterogeneity, the
random-effects model was used. Data analysis was performed with
Cochrane Review Manager for Windows (release 5.0.24, the Cochrane
Collaboration, Copenhagen, Denmark).
Results
Search results
The selection of the included randomized clinical trials is shown in
Figure 1. The search retrieved 435 potential relevant manuscripts.
A total of 372 were excluded after the examination of the title
and abstract. Of the 63 articles retrieved for further examination,
8 randomized clinical trials of ICD therapy for primary prevention
were included for the analysis. No evidence of publication bias was
found by funnel-plot analysis.
Qualitative ﬁndings
The included trials were randomized and controlled. The analysed
primary prevention trials were the Multicenter Automatic Deﬁbrilla-
tor Implantation Trial (MADIT),
3 the Coronary Artery Bypass Graft
Patch trial (CABG Patch),
16 the Cardiomyopathy Trial (CAT),
17
Figure 1 Selection of trials included in the meta-analysis.
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5 the Amiodarone vs. Implantable Cardioverter-
Deﬁbrillator Randomized Trial (AMIOVIRT),
18 the Deﬁbrillator in
Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)
trial,
19 the Deﬁbrillators in Acute Myocardial Infarction Trial
(DINAMIT),
20 and the Sudden Cardiac Death in Heart Failure
Trial (SCD-HeFT).
6 The Multicenter Unsustained Tachycardia Trial
(MUSTT) and the Comparison of Medical Therapy, Pacing and Deﬁ-
brillators in Chronic Heart Failure (COMPANION) trial were
excluded from the analysis.
21,22 The MUSTT trial was not a random-
ized controlled trial of ICD therapy, but compared with electro-
physiological study guided antiarrhythmic therapy, including Class Ic
drugs, in this way selecting patients for ICD therapy with empirical
therapy. It is well known that Ic drugs are proarrhythmic.
23,24 The
COMPANIONtrialwasnotacomparisonbetweenICDandconven-
tional therapy, but studied the effects of CRT in a subgroup with
pacing and a subgroup with ICDs, and therefore is not reporting on
the effect of ICD-only therapy.
The characteristics of the included trials are presented in
Table 1. In the eight trials, 5343 patients were randomly assigned
to ICD therapy or conventional therapy. Of these trials, four
trials evaluated patients with ischaemic heart disease (MADIT,
CABG Patch, MADIT II, and DINAMIT), three trials examined
patients with non-ischaemic heart disease (CAT, AMIOVIRT, and
DEFINITE), and one trial (SCD-HeFT) enrolled patients with
CAD and DCM.
The baseline clinical characteristics of patients are presented in
Table 2. The mean age of the trial participants was 60 years, 79%
were male, and CAD was present in 73%. The mean LVEF was
25% (range 21–28%), 59% of patients had New York Heart
Association (NYHA) Class II heart failure symptoms, and 26%
NYHA Class III.
Quantitative ﬁndings
All-cause mortality
Coronary artery disease
The MADIT, MADIT II, and SCD-HeFT trials showed signiﬁcant
reductions in all-cause mortality with relative risk (RR) reductions
ranging from 22 to 59%. In CABG Patch and DINAMIT, no
reductions in all-cause mortality were found (RR: 1.07; 95% CI:
0.81–1.42, and RR: 1.08; 95% CI: 0.76–1.55, respectively). All
these trials, except DINAMIT, mandated that patients should be
enrolled if they were at least 3 weeks after myocardial infarction.
Deﬁbrillators in Acute Myocardial Infarction Trial was the only
study designed to test ICD therapy as primary prevention in
patients recovering from an acute myocardial infarction. The
MADIT, MADIT II, and SCD-HeFT trials excluded patients who
underwent coronary revascularization within 1 month before
enrolment, whereas in CABG Patch, patients were enroled at
the time of coronary artery bypass surgery.
When the results of the ﬁve randomized trials were pooled, we
found statistical evidence of heterogeneity (I
2 ¼ 74.9%; P ¼ 0.003).
To assess the impact of heterogeneity on the pooled effect esti-
mate, we performed sensitivity analysis (Table 3). After exclusion
of CABG Patch and DINAMIT, no statistical evidence of hetero-
geneity was present (I
2 ¼ 61.5%; P ¼ 0.07). Pooled analysis using
a ﬁxed-effects model of the remaining studies showed a 29% RR
...............................................................................................................................................................................
Table 1 Characteristics of included studies
Study Inclusion criteria Patients
(n)
ICD
(n)
Follow-up
(months)
Main result
MADIT, 1996 EF ≤0.35; MI ≥3 weeks before entry; NSVT;
NYHA I–III
196 95 27 ICD therapy resulted in 54% RR
reduction, P ¼ 0.009
CABG Patch,
1997
EF ≤0.35; abnormal SAECG, scheduled for
CABG; NYHA I–III
900 446 32 ICD therapy did not reduce mortality,
P ¼ 0.64
CAT, 2002 EF ≤0.30; new onset DCM; NYHA II–III 104 50 66 ICD therapy did not reduce mortality,
P ¼ 0.55
MADIT II, 2002 EF ≤0.30; MI ≥1 month before entry; NYHA
I–III
1232 742 20 ICD therapy resulted in 31% RR
reduction, P ¼ 0.016
AMIOVIRT,
2003
EF ≤0.35; DCM; asymptomatic NSVT; NYHA
I–III
103 51 36 ICD therapy did not reduce mortality,
P ¼ 0.80
DEFINITE, 2004 EF ≤0.35; DCM; NSVT, NYHA I–III 458 229 29 ICD therapy resulted in 35% RR
reduction, P ¼ 0.08
DINAMIT, 2004 EF ≤0.35; within 6–40 days of MI; NYHA
I–III; abnormal HRV
674 332 33 ICD therapy did not reduce mortality,
P ¼ 0.66
SCD-HeFT,
2005
EF ≤0.35; 3 months optimal medical therapy;
NYHA II–III
2521 829 45.5
a ICD therapy resulted in 23% RR
reduction, P ¼ 0.007
AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CABG Patch, Coronary Artery Bypass Graft Patch trial; CAT, Cardiomyopathy Trial; DCM, dilated
cardiomyopathy; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Deﬁbrillator in Acute Myocardial Infarction Trial; EF, left
ventricular ejection fraction; HRV, heart rate variability; MADIT, Multicenter Automatic Deﬁbrillator Implantation Trial; MI, myocardial infarction; NYHA, New York Heart
Association; NSVT, non-sustained ventricular tachycardia; SAECG, signal-averaged ECG; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
aMedian
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39%; P , 0.0001). Analysis with a random-effects model yielded
a 33% RR reduction in all-cause mortality (95% CI: 12–49%; P ¼
0.004).
Dilated cardiomyopathy
A tendency towards a reduction in all-cause mortality by ICD
therapy was found in two trials (DEFINITE and SCD-HeFT). The
DEFINITE trial showed a RR of 0.65 for all-cause mortality with
ICD therapy (95% CI: 0.40–1.06; P ¼ 0.08). The RR for all-cause
mortality was 0.74 in the SCD-HeFT trial (95% CI: 0.55–1.00).
The CAT and AMIOVIRT trials found no reduction in all-cause
mortality with ICD therapy compared with conventional therapy.
When we pooled the data, the RR for all-cause mortality was
0.74 (95% CI: 0.59–0.93; P ¼ 0.009) both in random- and
ﬁxed-effects models. No statistical evidence for heterogeneity
was present among the trials enroling patients with DCM (I
2 ¼
0%; P ¼ 0.98).
Combined analysis
When we pooled the data of CAD and DCM, the summary of RR
for all-cause mortality was 0.72 (95% CI: 0.64–0.82; P , 0.0001)
with ICD therapy (Figure 2). No statistical evidence of heterogen-
eity was found (I
2 ¼ 0%; P ¼ 0.49). The pooled analysis using a
ﬁxed-effects model demonstrates that ICD therapy signiﬁcantly
reduces the all-cause mortality, both in patients with CAD (RR:
0.71; 95% CI: 0.61–0.83) and DCM (RR: 0.74; 95% CI: 0.59–
0.93). No signiﬁcant differences in ICD beneﬁt were found
between ischaemic and non-ischaemic heart disease (I
2 ¼ 0%;
P ¼ 0.82).
Arrhythmic mortality
Combined analysis
Among the 2774 patients randomized to ICD therapy, there
were 98 sudden cardiac deaths compared with 227 sudden
cardiac deaths among the 2569 patients randomized to conven-
tional therapy. A pooled analysis using a ﬁxed-effects model
demonstrated a 60% relative reduction in arrhythmic mortality
(RR: 0.40; 95% CI: 0.31–0.50; P , 0.0001) with ICD therapy
(Figure 3). No statistical heterogeneity was found among the
trials (I
2 ¼ 0%; P ¼ 0.84). Subanalysis of SCD-HeFT demon-
strated a signiﬁcant reduction of arrhythmic mortality in CAD
(RR: 0.43; 95% CI: 0.27–0.67) and DCM (RR: 0.34; 95% CI:
0.17–0.70).
Implantable cardioverter-deﬁbrillator therapy during follow-up
The appropriateness of ICD therapy could not be assessed reliably
in the MADIT and in the CABG Patch trial, since only a small
number of devices had the capacity of electrogram storage. The
remaining six trials presented data on the number of patients
............. ....................................................................
...............................................................................................................................................................................
Table 2 Baseline clinical characteristics of patients assigned to implantable cardioverter-deﬁbrillator therapy
Study Age (years) Men (%) EF (%) NYHA
(%)
CAD (%) Pharmcological therapy (%)
II III Amiodarone b-blocker Digoxin ACE/ARB
MADIT 62+99 2 2 7 +7 II or III, 63 100 2 26 58 60
CABG Patch 64+98 7 2 7 +6 II or III, 71 100 4 18 69 55
CAT 52+12 86 24+6 67 33 0 NA 4 86 94
MADIT II 64+10 84 23+5 35 25 100 13 70 72 68
AMIOVIRT 58+11 67 22+10 64 16 0 NA 52 71 85
DEFINITE 58 73 21 54 21 0 4 86 42 97
DINAMIT 62+11 76 28+5 NA NA 100 8 87 NA 95
SCD-HeFT 60
a 76 25
a 71 29 52 NA 69 67 94
ACE/ARB, angiotensin-converting enzyme/angiotensin receptor blocker; AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CABG Patch, Coronary Artery
Bypass Graft Patch trial; CAT, Cardiomyopathy Trial; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; DINAMIT, Deﬁbrillator in Acute
Myocardial Infarction Trial; EF, left ventricular ejection fraction; MADIT, Multicenter Automatic Deﬁbrillator Implantation Trial; MI, myocardial infarction; NYHA, New York Heart
Association; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
aMedian.
................................................................................
Table 3 Sensitivity analysis of randomized primary
prevention trials in patients with ischaemic heart
disease
Study
removed
RR 95% CI Heterogeneity
(P-value)
ICD
beneﬁt
(P-value)
MADIT 0.87 0.77–0.99 0.04 0.03
CABG
Patch
0.77 0.68–0.88 0.01 0.0002
MADIT II 0.88 0.77–1.00 0.003 0.05
DINAMIT 0.80 0.70–0.91 0.005 0.0005
SCD-HeFT 0.86 0.74–1.00 0.002 0.05
Removal of each trial (shown in column 1) followed by re-analysis of the pooled
relative risk (RR; column 2) and 95% conﬁdence intervals (95% CIs; column 3) for
the remaining trials. P-values for heterogeneity and ICD beneﬁt are shown in
columns 4 and 5.
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lar tachyarrhythmias (Figure 4). The mean proportion of patients
with appropriate ICD therapy was 22.9% (range 17.8–31.4%).
The delivery of inappropriate ICD therapy was observed in
16.5% of the patients.
Discussion
Arrhythmic death and implantable
cardioverter-deﬁbrillator interventions
Previous meta-analyses demonstrated that the ICD is associated
with a 50% RR reduction for arrhythmic death in secondary pre-
vention patients.
25,26 In primary prevention, the risk reduction
for arrhythmic death is similar. In SCD-HeFT, as was conﬁrmed
in this analysis, the beneﬁt of ICD therapy in reducing arrhythmic
death is similar, regardless of whether a patient had left ventricular
dysfunction caused by CAD or DCM.
27 The proportion of ICD
interventions in the follow-up cannot be used as a surrogate for
its efﬁcacy in preventing mortality, but shows that ICDs are effec-
tive in terminating ventricular arrhythmias.
All-cause mortality
Incontrasttoarrhythmicmortality,theresultsonall-causemortality
areheterogeneous.Weconﬁrmedwiththismeta-analysisthatthere
isasubstantialbeneﬁt (ariskreductionof27%),whichiscomparable
with former analysis.
28 Former meta-analysis did not exclude
DINAMIT and CABG Patch, which both contributed signiﬁcantly
in the heterogeneity of the pooled analysis in CAD. This resulted
in a homogeneous CAD population in our observation. The
observed beneﬁt for the entire group and for DCM remains
present in spite of the inclusion of small negative trials studying
DCM, and additional exclusion of trials such as MUSTT, comparing
ICD therapy with potentially proarhythmic drug therapy as
control.
23,24 Further, in contrast to previous meta-analyses,
26,28–30
we excluded trials with a potential beneﬁt of CRT (as COMPA-
NION), as CRT alone already has a beneﬁt on survival.
9,10 This is
part of the explanation that ICD therapy in non-ischaemic cardio-
myopathy only received a recommended Class I-B indication in the
2006 and 2008 international guidelines.
7,8 The beneﬁt of CRT is
most evident in patients with DCM and left bundle branch block,
31
but its impact on mortality in comparison with ICD was not
evident in a recent study in patients with mild heart failure,
32 con-
ﬁrming our position that the beneﬁt of both intervention
modalities (ICD and CRT) should be further clariﬁed.
Implantable cardioverter-deﬁbrillator-
only beneﬁt
A huge variation exists in the utilization of ICDs with or without
CRT in different social and medical environments.
33 Uncertainty
Figure 2 All-cause mortality among patients with ischaemic or non-ischaemic heart disease randomized to implantable cardioverter-
deﬁbrillator (ICD) vs. conventional therapy in primary prevention. For each randomized trial, the number of deaths (Events) and the
number assigned (Total) are shown. The point estimates of the relative risk (RR) for individual studies are represented by squares with
95% conﬁdence intervals (CIs) shown as bars. The midpoint of the diamond represents the overall pooled estimate of the RR, and the 95%
CI is represented by the horizontal tips of the diamond. AMIOVIRT, Amiodarone vs. Implantable Deﬁbrillator Randomized Trial; CAT, Cardi-
omyopathy Trial; DEFINITE, Deﬁbrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation; MADIT, Multicenter Automatic Deﬁbrilla-
tor Implantation Trial; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
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therapy, and doubts on the value of ICDs for DCM, e.g. in the
Dutch guidelines,
34 prompted us to perform this meta-analysis,
which was performed for the ﬁrst time with unpublished data on
SCD-HeFT (separate mortality data for ischaemic and non-
ischaemic cardiomyopathy).
The timing of device implantation after myocardial infarction
remains debated. The role of ICD therapy in the early post-
myocardial infarction period was examined by the DINAMIT
study.
20 No beneﬁt of ICD therapy in reducing all-cause mortality
was observed when device implantation occurred within 40 days
post-acute myocardial infarction. A recent study, Immediate Risk
Stratiﬁcation Improves Survival (IRIS), that included patients very
early after infarction with additional risk factors conﬁrmed this
ﬁnding.
35 Time-dependent beneﬁt of ICD therapy was observed
in the MADIT II study.
36 Beneﬁt was present for remote events
more than 18 months after myocardial infarction, as could be
expected from other observations.
2
Thus, this analysis conﬁrms that ICD-only therapy reduces the
RR for all-cause mortality by 27% for patients with a LVEF
≤35%, if they are 40 days from myocardial infarction and ≥3
months from a coronary revascularization procedure, without a
previous cardiac arrest or symptomatic ventricular arrhythmias.
This beneﬁcial effect of ICD-only therapy on survival exists regard-
less of whether a patient has left ventricular dysfunction due to
CAD or DCM.
Study limitations
Our analysis has several limitations. First, we could not obtain indi-
vidual patient data, which offers the possibility to explore sub-
groups which may beneﬁt more or less from ICD therapy. The
conclusions of this analysis are limited by the available data.
Another possible limitation of our analysis is the inﬂuence of pub-
lication bias. This type of bias was minimized by an extensive search
and through the inclusion of unpublished data in our analysis. We
performed funnel-plot analysis which did not indicate publication
bias, although the power is limited due to the small number of
included studies.
Conclusion
The results of our meta-analysis provide strong evidence support-
ing the beneﬁcial effect of ICD-only therapy on survival of patients
with LVEF ≤35% due to ischaemic or non-ischaemic heart disease,
if they are 40 days from myocardial infarction and at least 3 months
from a coronary revascularization procedure.
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Figure 3 Arrhythmic mortality among primary prevention trials. For each randomized trial, the number of deaths (n) and the number
assigned (N) are shown. The point estimates of the relative risk (RR) for individual studies are represented by squares with 95% conﬁdence
intervals (CIs) shown as bars. The midpoint of the diamond represents the overall pooled estimate of the RR, and the 95% CI is represented
by the horizontal tips of the diamond. Abbreviations are the same as in Figure 1.
Figure 4 Rates of appropriate implantable cardioverter-
deﬁbrillator therapy. Abbreviations are the same as in Figure 1.
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